Pharmaceutical stocks are some of the biggest in the FTSE 100. The sector is threatened by tariffs, but some have posted encouraging results regardless.

The FTSE 100 enjoyed another leap towards record territory as the index pushed around 0.7 per cent higher on Tuesday, following strong earnings reports from the likes of AstraZeneca and Barclays.

Early data from the DURIPANC study shows promising safety and survival benefits of rintatolimod and durvalumab for metastatic ...

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

In terms of its transformative effect, AI is doing for healthcare what electricity did for the industry. According to Fortune ...

FTSE 100 climbs as earnings cascade brings cheer - Shares of Games Workshop, AstraZeneca, Barclays and Entain moved higher.

Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” second-quarter 2025 investor ...

AstraZeneca PLC AZN has struck a deal to buy a portfolio of gene therapies from Pfizer Inc. PFE for up to $1 billion, the biopharma company announced Friday. The deal, expected to close in the ...

Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

The pharmaceutical giant said second-quarter revenue increased to $14.46 billion from $12.94 billion. U.S. revenue was up 13% ...

Two diabetes drugs could become more affordable for Maryland residents, following a study by the Prescription Drug ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 billion in manufacturing.